JP2021130713A - 新規な免疫賦活法 - Google Patents
新規な免疫賦活法 Download PDFInfo
- Publication number
- JP2021130713A JP2021130713A JP2021093836A JP2021093836A JP2021130713A JP 2021130713 A JP2021130713 A JP 2021130713A JP 2021093836 A JP2021093836 A JP 2021093836A JP 2021093836 A JP2021093836 A JP 2021093836A JP 2021130713 A JP2021130713 A JP 2021130713A
- Authority
- JP
- Japan
- Prior art keywords
- tlr2
- pam2cys
- mice
- immune response
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本明細書を通して、文脈が他のことを要求していない限り、「含む(comprise)」という語又は「含む(comprises)」若しくは「含んでいる(comprising)」などの変化形は、述べられている要素若しくは整数又は要素若しくは整数の群の組み入れを意味し、任意の他の要素若しくは整数又は要素若しくは整数の群の除外を意味するものではないと理解されるものとする。
ペプチド及びリポペプチドの合成、精製及び確証。リポペプチド及びペプチドの合成を、従来の固相合成により、全体にわたって、Fmoc(9−フルオレニルメトキシ カルボニル)化学を使用して実施した。ペプチドを、Symphony Multiplex synthesiser(Protein Technologies Inc、Arizona、USA)又はマイクロ波技術を使用して高忠実性ペプチド配列の作製を容易にするLiberty synthesiser(CEM、North Carolina、USA)使用して、自動的にアセンブリさせた。ペプチド及びリポペプチドを、逆相高性能液体クロマトグラフィーにより精製し、生成物の信頼性を、質量分析により決定した。ペプチドのアセンブリ、精製及び特徴付けに使用した手順は、他に詳細に記載されている(参考文献1、2、3)。Pam2Cysの可溶性形態を、O−(N−Fmoc−2−アミノエチル)−O’−(2−カルボキシエチル)−ウンデカエチレングリコール(Fmoc−PEG11−OH、Merck Ltd)のPam2Cysへの付加により調製した。これにより、脂質のペグ化形態、Pam2Cys−PEG11が形成された。リポペプチド構築体及び個別のリポペプチド組成物に含まれるエピトープを表1に示す。
Pam2Cysに基づくリポペプチド接種が、肺細胞集団を拡大する。肺細胞環境に対するPam2Cysに基づくリポペプチドの効果を、ヘルパーTエピトープ(Th)OT2及び単純ヘルペスウイルス1由来CD8+T細胞エピトープを含有するリポペプチドOT2−P2C−gB498−505(gB498−505;表1を参照されたい)を鼻腔内接種されたC57BL/6マウスにおいて検査した。PBSで還流された肺における肺常在細胞集団を、細胞フローサイトメトリを使用して特徴付けた。
先天性免疫応答が感染症の制御において果たすきわめて重要な役割は、感染前の先天性免疫系の早期活性化が、感染因子、例えばウイルス又は細菌によるチャレンジに対する保護強化を提供できることを示唆している。この研究の結果は、TLR2アゴニストを含む可溶性TLR2部分の投与が、投与された対象において先天性免疫応答を高め、免疫応答が非抗原特異的であることを明示した。さらに、本発明に従った組成物の鼻腔内予防投与により誘発される肺の変化がウイルス及び細菌への続く曝露に対する抵抗性の増加に関係した。このような組成物が、ウイルス感染症及び細菌感染症に対する予防薬として、特に流行又はパンデミックの発生の高い危険性がある場合、適切であることを示唆している。本発明に従った予防方法及び治療方法はまた、感染因子(又はその抗原成分若しくは特定の菌株)の予備知識を必要としないという有利性を有し、したがって、例えばインフルエンザのパンデミックの期間に特に有用であり得る。凍結乾燥でき、室温において安定である、本発明に従った組成物の安定性は、パンデミックの状況に対する備蓄に非常に適切であることもまた意味する。
Claims (20)
- 対象において先天性免疫応答を高めることにより疾患を治療又は予防する方法であって、
溶液中にTLR2部分を含む有効量の組成物を対象に投与するステップを含み、
TLR2部分がTLR2アゴニストを含み、
疾患が、TLR2部分に対する液性免疫応答又は細胞性免疫応答により治療又は予防されない、方法。 - 対象において先天性免疫応答を高めることによりがんを治療又は予防する方法であって、
溶液中にTLR2部分を含む治療有効量の組成物を対象に投与するステップを含み、
TLR2部分がTLR2アゴニストを含み、
TLR2部分が、がんに対する特異的細胞性免疫応答又は液性免疫応答を誘導しない、方法。 - 感染因子により引き起こされる疾患を治療又は予防する方法であって、
溶液中にTLR2部分を含む有効量の組成物を、それを必要とする対象に投与するステップを含み、
TLR2部分がTLR2アゴニストを含み、
TLR2部分が感染因子に対する特異的な細胞性免疫応答又は液性免疫応答を誘導しない、方法。 - TLR2部分が、可溶化剤にコンジュゲートされたTLR2アゴニストを含む、請求項1〜3のいずれか一項に記載の方法。
- TLR2アゴニストが、Pam2Cys、Pam3Cys、Ste2Cys、Lau2Cys及びOctCysからなる群から選択される、請求項1〜4のいずれか一項に記載の方法。
- TLR2アゴニストがPam2Cysである、請求項5に記載の方法。
- 可溶化剤がPEG(ポリエチレングリコール)又は極性ポリペプチドである、請求項4〜6のいずれか一項に記載の方法。
- 極性ポリペプチドが、R4、H4、E8及びH8からなる群から選択される、請求項7に記載の方法。
- 可溶化剤がPEGである、請求項7に記載の方法。
- 可溶化剤が、PEG並びにR4、H4、H8、EB8及びE8のいずれか1つを含む、請求項7に記載の方法。
- 組成物が対象に鼻腔内投与される、請求項1〜10のいずれか一項に記載の方法。
- 感染因子がウイルスである、請求項3〜11のいずれか一項に記載の方法。
- ウイルスがインフルエンザAウイルス(IAV)である、請求項12に記載の方法。
- 感染因子が、マイコバクテリウム・ツベルクローシス又はレジオネラ・ニューモフィラである、請求項3〜11のいずれか一項に記載の方法。
- がんが感染因子により引き起こされる、請求項2に記載の方法。
- がんが、ヒトパピローマウイルス(HPV)、C型肝炎ウイルス(HCV)又はエプスタイン・バーウイルス(EBV)により引き起こされる、請求項15に記載の方法。
- 溶液中の有効量のTLR2部分を、薬学的に許容される担体又は賦形剤と一緒に含む、対象において先天性免疫応答を高めることにより疾患を治療又は予防するための医薬組成物であって、
TLR2部分がTLR2アゴニストを含み、
疾患が、TLR2部分に対する液性免疫応答又は細胞性免疫応答により治療又は予防されない、医薬組成物。 - 対象において疾患を治療又は予防するための医薬品の製造のための、溶液中の有効量のTLR2部分の使用であって、
TLR2部分がTLR2アゴニストを含み、
TLR2アゴニストが対象において先天性免疫応答を高め、
疾患が、TLR2部分に対する液性免疫応答又は細胞性免疫応答により治療又は予防されない、使用。 - 組成物がTLR9アゴニストを含まない、請求項1〜16のいずれか一項に記載の方法又は請求項17に記載の組成物。
- 医薬品がTLR9アゴニストを含まない、請求項18に記載の使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023095418A JP2023113902A (ja) | 2010-09-22 | 2023-06-09 | 新規な免疫賦活法 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010904284 | 2010-09-22 | ||
AU2010904284A AU2010904284A0 (en) | 2010-09-22 | Novel Immunostimulatory Method | |
AU2011902408A AU2011902408A0 (en) | 2011-06-20 | Novel immunstimulatory method | |
AU2011902408 | 2011-06-20 | ||
JP2019105433A JP7497962B2 (ja) | 2010-09-22 | 2019-06-05 | 新規な免疫賦活法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019105433A Division JP7497962B2 (ja) | 2010-09-22 | 2019-06-05 | 新規な免疫賦活法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023095418A Division JP2023113902A (ja) | 2010-09-22 | 2023-06-09 | 新規な免疫賦活法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021130713A true JP2021130713A (ja) | 2021-09-09 |
Family
ID=45873313
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013529510A Withdrawn JP2013537892A (ja) | 2010-09-22 | 2011-09-22 | 新規な免疫賦活法 |
JP2016216593A Active JP6657507B2 (ja) | 2010-09-22 | 2016-11-04 | 新規な免疫賦活法 |
JP2019105433A Active JP7497962B2 (ja) | 2010-09-22 | 2019-06-05 | 新規な免疫賦活法 |
JP2021093836A Withdrawn JP2021130713A (ja) | 2010-09-22 | 2021-06-03 | 新規な免疫賦活法 |
JP2023095418A Pending JP2023113902A (ja) | 2010-09-22 | 2023-06-09 | 新規な免疫賦活法 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013529510A Withdrawn JP2013537892A (ja) | 2010-09-22 | 2011-09-22 | 新規な免疫賦活法 |
JP2016216593A Active JP6657507B2 (ja) | 2010-09-22 | 2016-11-04 | 新規な免疫賦活法 |
JP2019105433A Active JP7497962B2 (ja) | 2010-09-22 | 2019-06-05 | 新規な免疫賦活法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023095418A Pending JP2023113902A (ja) | 2010-09-22 | 2023-06-09 | 新規な免疫賦活法 |
Country Status (10)
Country | Link |
---|---|
US (5) | US9676819B2 (ja) |
EP (3) | EP3669892B1 (ja) |
JP (5) | JP2013537892A (ja) |
CN (2) | CN105477640B (ja) |
AU (1) | AU2011305061B2 (ja) |
CA (1) | CA2811957C (ja) |
DK (1) | DK2618842T3 (ja) |
ES (1) | ES2735274T3 (ja) |
PL (1) | PL2618842T3 (ja) |
WO (1) | WO2012037612A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2735274T3 (es) | 2010-09-22 | 2019-12-17 | Ena Therapeutics Pty Ltd | Nuevo método inmunoestimulador |
AU2014300503B2 (en) | 2013-06-28 | 2018-11-22 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
WO2016037240A1 (en) * | 2014-09-12 | 2016-03-17 | The University Of Melbourne | Immunological reagent |
JP2018505152A (ja) | 2014-12-23 | 2018-02-22 | アン ブリンブル マーガレット | アミノ酸複合体及びペプチド複合体ならびにそれらの使用 |
CA3014515A1 (en) | 2016-02-26 | 2017-08-31 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
CN118161614A (zh) * | 2017-03-31 | 2024-06-11 | 艾娜呼吸私人有限公司 | 用tlr2激动剂治疗呼吸道感染 |
US20210177795A1 (en) * | 2017-12-21 | 2021-06-17 | Ena Therapeutics Pty Ltd | Administering compounds |
EP4025204A4 (en) * | 2019-09-04 | 2023-10-11 | Axelia Oncology Pty Ltd | CANCER IMMUNOTHERAPY |
US20220347146A1 (en) * | 2019-09-04 | 2022-11-03 | Axelia Oncology Pty Ltd | Cancer treatment |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004508292A (ja) * | 2000-05-19 | 2004-03-18 | コリクサ コーポレイション | 単糖類及び二糖類に基づく化合物を用いた感染症及び他の疾患の予防的並びに治療的な処置 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4119856A1 (de) | 1991-06-17 | 1992-12-24 | Hoechst Ag | N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen |
DE60039715D1 (de) | 1999-11-19 | 2008-09-11 | Csl Ltd | Hcv-impfstoff zusammensetzungen |
EP1382352A1 (de) * | 2002-07-19 | 2004-01-21 | GBF Gesellschaft für Biotechnologische Forschung mbH | Bisacyloxypropylcystein-Konjugate und deren Verwendung |
EP2314630A1 (en) * | 2002-08-12 | 2011-04-27 | The Council Of The Queensland Institute Of Medical Research | Method of producing immunogenic lipopeptides comprising T-helper and Cytotoxic T Lymphocyte (CTL) epitopes |
JP4619120B2 (ja) | 2002-08-12 | 2011-01-26 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | Tヘルパーエピトープおよびb細胞エピトープを含む新規な免疫原性リポペプチド |
EP1550458A1 (en) | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Synergistic liposomal adjuvants |
CN1921877A (zh) * | 2004-01-16 | 2007-02-28 | 悉生物有限公司 | 陪伴蛋白10对Toll样受体诱导的细胞因子和趋化因子分泌的调节 |
WO2005079419A2 (en) | 2004-02-17 | 2005-09-01 | The Regents Of The University Of California | Methods of treating immunopathological disorders |
GB0405634D0 (en) | 2004-03-12 | 2004-04-21 | Univ Southampton | Anti-virus therapy for respiratory diseases |
GB0411411D0 (en) | 2004-05-21 | 2004-06-23 | Glaxosmithkline Biolog Sa | Vaccines |
BRPI0516356A (pt) | 2004-10-18 | 2008-09-02 | Globeimmune Inc | terapia à base de levedura para infecções crÈnicas da hepatite c |
EP1666056A1 (en) | 2004-12-06 | 2006-06-07 | Bestewil Holding B.V. | Cancer vaccine vesicles |
MX2007007586A (es) * | 2004-12-21 | 2007-12-10 | Vaxinnate Corp | Composiciones de proteinas de virus de gripe y metodos de uso de las mismas. |
US20100129385A1 (en) * | 2005-02-08 | 2010-05-27 | Jackson David C | Immunogenic molecules |
WO2006091591A1 (en) | 2005-02-22 | 2006-08-31 | The Regents Of The University Of California | Methods of treating gastrointestinal inflammation |
WO2008085549A2 (en) | 2006-07-28 | 2008-07-17 | Board Of Regents Of The University Of Texas System | Compositions and methods for stimulation of lung innate immunity |
EP2200638B1 (en) * | 2007-10-09 | 2016-03-16 | The University of Melbourne | Compositions for the transfection of cells |
WO2009137103A2 (en) | 2008-05-09 | 2009-11-12 | Ourth Donald D | Anti-cancer/anti-viral compounds and methods of use |
WO2009155332A1 (en) * | 2008-06-17 | 2009-12-23 | Cedars-Sinai Medical Center | Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors |
JP5699081B2 (ja) * | 2008-09-05 | 2015-04-08 | アイ ディー バイオメディカル コーポレーション オブ ケベック | 新規の組成物及びアジュバント |
JP2012517428A (ja) | 2009-02-11 | 2012-08-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Toll様レセプター調節因子および疾患の処置 |
PT2411521E (pt) | 2009-03-25 | 2015-04-21 | Univ Texas | Composições para estimulação de resistência imunitária inata de mamíferos contra patogénicos |
JP2012523379A (ja) | 2009-04-09 | 2012-10-04 | ザ ユニバーシティー オブ メルボルン | 免疫原性組成物およびその使用 |
EP2338521A1 (en) | 2009-12-28 | 2011-06-29 | Helmholtz-Zentrum für Infektionsforschung GmbH | Lipopeptide- and lipoprotein-conjugates and its use |
JP5848748B2 (ja) | 2010-03-23 | 2016-01-27 | アイアールエム・リミテッド・ライアビリティ・カンパニーIrm,Llc | 感染症、炎症、呼吸器疾患などの処置に使用するtlr2アゴニストとしての化合物(システインベースのリポペプチド)および組成物 |
ES2735274T3 (es) * | 2010-09-22 | 2019-12-17 | Ena Therapeutics Pty Ltd | Nuevo método inmunoestimulador |
WO2016037240A1 (en) | 2014-09-12 | 2016-03-17 | The University Of Melbourne | Immunological reagent |
-
2011
- 2011-09-22 ES ES11826223T patent/ES2735274T3/es active Active
- 2011-09-22 PL PL11826223T patent/PL2618842T3/pl unknown
- 2011-09-22 CN CN201510939940.1A patent/CN105477640B/zh active Active
- 2011-09-22 WO PCT/AU2011/001225 patent/WO2012037612A1/en active Application Filing
- 2011-09-22 JP JP2013529510A patent/JP2013537892A/ja not_active Withdrawn
- 2011-09-22 CA CA2811957A patent/CA2811957C/en active Active
- 2011-09-22 CN CN201180051461.6A patent/CN103189072B/zh active Active
- 2011-09-22 DK DK11826223.7T patent/DK2618842T3/da active
- 2011-09-22 EP EP20155567.9A patent/EP3669892B1/en active Active
- 2011-09-22 EP EP19163679.4A patent/EP3520814A1/en not_active Withdrawn
- 2011-09-22 AU AU2011305061A patent/AU2011305061B2/en active Active
- 2011-09-22 EP EP11826223.7A patent/EP2618842B1/en active Active
- 2011-09-22 US US13/825,679 patent/US9676819B2/en active Active
-
2016
- 2016-11-04 JP JP2016216593A patent/JP6657507B2/ja active Active
-
2017
- 2017-05-16 US US15/596,427 patent/US10406100B2/en active Active
-
2019
- 2019-06-05 JP JP2019105433A patent/JP7497962B2/ja active Active
- 2019-07-26 US US16/522,779 patent/US11351114B2/en active Active
-
2021
- 2021-06-03 JP JP2021093836A patent/JP2021130713A/ja not_active Withdrawn
-
2022
- 2022-05-24 US US17/664,717 patent/US11786458B2/en active Active
-
2023
- 2023-06-09 JP JP2023095418A patent/JP2023113902A/ja active Pending
- 2023-10-10 US US18/483,662 patent/US20240050364A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004508292A (ja) * | 2000-05-19 | 2004-03-18 | コリクサ コーポレイション | 単糖類及び二糖類に基づく化合物を用いた感染症及び他の疾患の予防的並びに治療的な処置 |
Non-Patent Citations (6)
Title |
---|
AM J RESPIR CELL MOL BIOL, VOL.40, P.474-481 (2009), JPN6019035330, 2009, ISSN: 0004793858 * |
BIOCHEMICAL JOURNAL, vol. 267, no. 3, JPN6015029342, 1990, pages 795 - 802, ISSN: 0004793855 * |
BIOLOGICAL CHEMISTRY HOPPE−SEYLER, vol. 370, no. 6, JPN6015029343, 1989, pages 575 - 582, ISSN: 0004793856 * |
JOURNAL OF DRUG TARGETING, vol. 17, no. 8, JPN6015029344, 2009, pages 662 - 670, ISSN: 0004793857 * |
PLOS ONE, vol. Vol.5,No.9,e12550, JPN6015029341, 2 September 2010 (2010-09-02), pages 1 - 12, ISSN: 0004793854 * |
上原記念生命科学財団研究報告集,23, JPN6019035331, 2009, JP, pages 1 - 5, ISSN: 0004793859 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021130713A (ja) | 新規な免疫賦活法 | |
JP7095053B2 (ja) | 免疫原性化合物 | |
Chua et al. | Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2 | |
EP2823824A1 (en) | Pharmaceutical composition containing peptide | |
CN102448485A (zh) | 免疫原性组合物及其用途 | |
AU2019264673A1 (en) | Vaccine compositions and methods for restoring NKG2D pathway function against cancers | |
Kelly et al. | Titrating polyarginine into nanofibers enhances cyclic-dinucleotide adjuvanticity in vitro and after sublingual immunization | |
US20210106652A1 (en) | Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation | |
Uchida et al. | Application of surface-linked liposomal antigens to the development of vaccines that induce both humoral and cellular immunity | |
NL2031833B1 (en) | Immunotherapeutic compositions and adjuvants | |
Deigin et al. | Peptide ILE-GLU-TRP (Stemokin) Potential Adjuvant Stimulating a Balanced Immune Response | |
Zeng et al. | Soluble Proteins Induce Strong CD8+ T Cell | |
US7314626B2 (en) | Use of peptide vectors to improve the immune response to antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210604 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210628 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220607 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220907 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221031 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20221206 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230214 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20230612 |